IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+22.57%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$329M
AUM Growth
+$61.1M
(+23%)
Cap. Flow
-$36.5M
Cap. Flow
% of AUM
-11.09%
Top 10 Holdings %
Top 10 Hldgs %
43.78%
Holding
155
New
31
Increased
13
Reduced
30
Closed
17
Top Buys
| 1 |
Celldex Therapeutics
CLDX
|
$21.4M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$15.7M |
| 3 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$9.46M |
| 4 |
Gossamer Bio
GOSS
|
$9.15M |
| 5 |
Black Diamond Therapeutics
BDTX
|
$7.49M |
Top Sells
| 1 |
BioXcel Therapeutics
BTAI
|
$22.5M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$21.5M |
| 3 |
argenx
ARGX
|
$14.4M |
| 4 |
Immunovant
IMVT
|
$13.6M |
| 5 |
MYOV
Myovant Sciences Ltd.
MYOV
|
$8.74M |
Sector Composition
| 1 | Healthcare | 96.18% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
151
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
0
| – | – |
|
152
Arvinas
ARVN
$559M
| – | – |
0
| – | – |
|
153
Arrowhead Research
ARWR
$3.87B
| – | – |
0
| – | – |
|
154
iShares China Large-Cap ETF
FXI
$6.55B
| – | – |
0
| – | – |
|